Research & Trial Information

SCHEMA S1500

Protocol#: SWOG – S1500

Cancer Type: GU Renal

ELIGIBILITY CRITERIA

1. . Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection. (NOTE: A designation of type I or type II should be made by the local pathologist if possible.) Mixed histologies containing type I or type II will be allowed provided that they contain ≥ 50% of the papillary component.
2. Patients must also have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (see Section 10.1). Disease X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration. If there is clinical suspicion for bone metastases at the time of enrollment (at the discretion of the investigator), bone scan should be performed at baseline (within 42 days prior to registration).
3. Patients with a history of treated brain metastases who are asymptomatic and have not received steroid therapy in the 14 days prior to registration are eligible. Anti-seizure medications are allowed provided they are non-enzyme inducing (e.g. topiramate, levatiracetam, gabapentin).
4. Patients must not have cavitating pulmonary lesions. Patients must not have tumor invading the GI tract or evidence of endotracheal or endobronchial tumor within 28 days prior to registration.
5. Patients may have received prior surgery. At least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery.
6. Patients may have received up to one prior systemic therapy for advanced or metastatic renal cell carcinoma with the exception of another VEGF inhibitor FDA-approved for advanced RCC (i.e., pazopanib, bevacizumab, sorafenib or axitinib). If a patient develops metastatic disease within six months of discontinuation of adjuvant therapy, this will constitute one prior systemic therapy for advanced or metastatic RCC. If a patient develops metastatic disease and more than six months has elapsed since discontinuation of adjuvant therapy, this will not constitute prior systemic therapy for advanced or metastatic RCC. Patients may have also received prior immunotherapy. Patients must not have received a MET/HGF inhibitor or sunitinib as prior therapy. At least 14 days must have elapsed since completion of prior systemic therapy. Patients must have recovered from all associated toxicities at the time of registration.
7. Patients may have received prior radiation therapy, but must have measurable disease outside the radiation port. At least 14 days must have elapsed since completion of prior radiation therapy. Patients must have recovered from all associated toxicities at the time of registration.
8. Patients must not be taking, nor plan to take while on protocol treatment, strong CYP3A4 inhibitors (e.g. boceprevir, cobicistat, danoprevir, elvitegravir/RIT, fluvoxamine, indinavir, itraconazole, ketoconazole, lopinavir/RIT, nefazodone, nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, tipravavir/RIT, or voriconazole,); strong CYP3A4 inducers (e.g. avasimibe, phenytoin, rifampin, rifabutin); potent inhibitors of CYP1A2 (e.g. ciprofloxacin); and/or drugs known to be CYP3A4 substrates with a narrow therapeutic range (e.g., diergotamine, ergotamine) within 14 days prior to randomization. (Moderate inhibitors or inducers of isoenzyme CYP3A4 should be avoided, but if necessary can be used with caution.
9. Patients must not be receiving or planning to receive any other investigational agents.
10. Patients must have a complete physical examination and medical history within 28 days prior to registration.
11. Patients must have a Zubrod performance status of 0 – 1.
12. Patients must have adequate hematologic function as documented by a WBC ≥ 2,000/mcL, an ANC ≥ 1,000/mcL, and a platelet count ≥ 75,000/mcL. These tests must be obtained within 28 days prior to registration.
13. Patients must have adequate hepatic function as evidenced by serum bilirubin ≤ 1.5 x institutional upper limits of normal (ULN). Serum transaminase (SGOT/AST and SGPT/ALT) must be ≤ 2.5 x the institutional ULN unless the liver is involved with the tumor, in which case serum transaminase (SGOT/SGPT) must be ≤ 5 x the institutional ULN. These tests must be obtained within 28 days prior to registration.
14. Serum creatinine must be ≤ 2 x the institutional ULN OR creatinine clearance (either measured or calculated) must be > 30 mL/min and obtained within 28 days prior to registration.
15. Patients must not have any clinical evidence of congestive heart failure (CHF) (specifically, New York Heart Association [NYHA] Class III [moderate] or Class IV [severe]) at the time of registration. Baseline echocardiogram within 28 days of registration must demonstrate an EF ≥ 50%. Due to the potential cardiac toxicity of the agents utilized in this protocol, patients must have QTc interval < 500 msec on prestudy EKG and no known history of congenital long QT syndrome. Patients must not have experienced unstable angina pectoris, clinically significant cardiac arrhythmias, or stroke (TIA or other ischemic event) within 3 months prior to registration and not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within 6 months of registration. Prestudy EKG must be obtained within 28 days prior to registration.